2026-04-14T04:42:53Zhttps://recercat.cat/oai/requestoai:recercat.cat:20.500.12327/16492025-10-22T11:19:18Zcom_2072_4428com_2072_4427col_2072_487898
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Pradenas, Edwards
Trinité, Benjamin
Urrea, Víctor
Marfil, Silvia
Tarrés-Freixas, Ferran
Ortiz, Raquel
Rovirosa, Carla
Rodon, Jordi
Serra Gironella, Joan
Segalés, Joaquim
Guallar, Victor
Valencia, Alfonso
Izquierdo-Useros, Nuria
Noguera-Julian, Marc
Carrillo, Jorge
Paredes, Roger
Mateu, Lourdes
Chamorro, Anna
Toledo, Ruth
Massanella, Marta
Clotet, Bonaventura
Blanco, Julià
Producció Animal
Sanitat Animal
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (>300 days from infection) responses in unvaccinated participants show a reduced efficacy against beta, but not alpha nor delta, variants. Multivariate analysis identifies the severity of primary infection as an independent determinant of higher magnitude and lower relative cross-neutralization activity of long-term neutralizing responses.
2025-10-22T11:19:18Z
2025-10-22T11:19:18Z
2025-10-22T11:19:18Z
2022-01-24
info:eu-repo/semantics/article
Pradenas, Edwards, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Rovirosa, Jordi Rodon, Júlia Vergara-Alert and Joaquim Segalés et al. 2022. "Clinical Course Impacts Early Kinetics,Magnitude, And Amplitude Of SARS-Cov-2 Neutralizing Antibodies Beyond 1 Year After Infection". Cell Reports Medicine 3 (2): 100523. doi:10.1016/j.xcrm.2022.100523.
2666-3791
http://hdl.handle.net/20.500.12327/1649
https://doi.org/10.1016/j.xcrm.2022.100523
eng
Cell Reports Medicine
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 International
Cell Press